Vertex Pharmaceuticals (VRTX) jumps 49% after the bell as the company says data from a Phase 2...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX) jumps 49% after the bell as the company says data from a Phase 2 study of a combined corrector/potentiator treatment for cystic fibrosis patients with two copies of the F508del gene mutation showed "statistically significant, dose-dependent, improvements in lung function.